Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-16 · accession 0000899243-23-013275 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-16 | LGND | KOZARICH JOHN W | Dir | S - Sale | $77.20 | -4,444 | 38.5K | -10% | -$343.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-16 | S | D | 4,444 | $77.20 | 38,488 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.20 to $77.24. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein. |